ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 310

Hyaluronic Acid Injections in Knee Osteoarthritis Patients Are Associated with Delay to Knee Arthroplasty

Kevin Ong1, Allen Anderson2, Edmund Lau3, Faizan Niazi4, Anke Fierlinger4, Steven Kurtz1 and Roy Altman5, 1Exponent, Inc., Philadelphia, PA, 2Tennessee Orthopaedic Alliance, Powderly, KY, 3Exponent, Inc., Menlo Park, CA, 4Ferring Pharmaceuticals, Inc., Parsippany, NJ, 5David Geffen School of Medicine, UCLA, Los Angeles, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: hyaluronate and osteoarthritis, Total Knee Arthroplasty (TKA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:
Although only few nonoperative treatment options for knee
osteoarthritis (OA) are available,
there continues to be debate about the effectiveness of hyaluronic acid (HA)
injections, particularly in light of recent clinical practice guidelines by
AAOS
and recommendations by OARSI, ACR, and recent systematic reviews. Thus, we investigated whether the formulation of
HA may be contributing to some of the reported variation in clinical outcomes.
This study evaluated whether the use of HA
injections is associated with a delay to knee arthroplasty
(KA) and whether there was a difference in effect size
by formulation of
HA injections.   Methods: A retrospective, observational study design based on the 5% sample
of Part B Medicare data from 200
7 to 2012 was used to
identify knee OA patients who underwent KA. The time to KA was compared between
patients who were coded with HA injection use (“HA”) and those who were not
(“no HA”), using quantile regression with propensity score adjustment. These were
further stratified
by HA formulation between bioengineered HA (high
molecular weight (HMW) and medium MW (MMW) Bio-HA) and non-bioengineered HA (high
MW (HMW) and low MW (LMW) non-Bio-HA).  

Results: A total of 23,008 knee OA patients (n=17,007
“no HA”; n=6,001 “HA”) subsequently underwent KA and were included in the study.
After adjusting for potential confounding patient factors and propensity scores,
the “HA” cohort was found to be associated with a delay to KA of 7.1 months
(95% CI: 6.6 to 7.5 months; p<0.001) compared to the “no HA” cohort. When
compared to the “no HA” cohort, patients who were treated with HMW Bio-HA were
found to have the longest time to KA over patients treated with other HA
formulations (Figure 1 and Table 1). However, when comparing between HA
formulations, LMW non-Bio-HA was found to have the shortest time to KA, while the
remaining three formulations had similarly longer time to KA (Table 1).

  Conclusion: Our
analysis of elderly
knee OA patients showed a
significantly longer delay to KA for those who were treated with HA. The delay
may provide additional time for patients to better control pre-existing
conditions prior to KA, which could aid in reducing postoperative morbidity.

Furthermore, there appears to be some differences in the effect of HA
formulation, in particular molecular weight, on the delay to KA.              

Figure 1: Survivorship curves (KA as the endpoint) for “no
HA” and “HA” cohorts.       Table 1. Difference in time to
KA (in months) between patient cohorts with propensity score adjustment (*positive
means more delay, negative means less delay)

Vs. no HA Difference in time to KA*
HMW non-Bio-HA +6.8 mos. (p<0.001)
LMW non-Bio-HA +7.6 mos. (p<0.001)
MMW Bio-HA +7.5 mos. (p<0.001)
HMW Bio-HA +8.6 mos. (p<0.001)
Vs. HMW Bio-HA Difference in time to KA*
HMW non-Bio-HA +0.5 mos. (p=0.387)
LMW non-Bio-HA -2.9 mos. (p<0.001)
MMW Bio-HA -0.8 mos. (p=0.175)
 

Disclosure: K. Ong, Ferring Pharmaceuticals, Stryker Orthopaedics, Biomet, Paradigm Spine, Pacira Pharmaceuticals, Medtronic, Stryker Mako Surgical,, 9,Zimmer, Ethicon, 9; A. Anderson, DePuy Mitek, 5,Acquire B2B, Web instruction, 9,AOSSM, Herodicus Society, Rock Group, 6,Am J Orthop, 8,OrthoPediatrics, Reconstruction system, ACL tears, 9; E. Lau, Ferring Pharmaceuticals, 9; F. Niazi, Ferring Pharmaceuticals, 3; A. Fierlinger, Ferring Pharmaceuticals, 3; S. Kurtz, Smith & Nephew; Stryker; Zimmer; Biomet; Depuy Synthes; Medtronic; Invibio; Stelkast; Formae; Kyocera Medical; Wright Medical Technology; Ceramtec; DJO; Celanese; Aesculap; Spinal Motion; Active Implants, Ferring Pharmaceuticals, 2,Exponent, Inc., 9; R. Altman, Cytori, Ferring, Iroko, Johnson & Johnson, Novartis, Oletec, Strategic sciences and Technologies, Teva, 5,Pfizer, Ferring, Oletec, Q Med, 9,Iroko, 8,Ferring, 9.

To cite this abstract in AMA style:

Ong K, Anderson A, Lau E, Niazi F, Fierlinger A, Kurtz S, Altman R. Hyaluronic Acid Injections in Knee Osteoarthritis Patients Are Associated with Delay to Knee Arthroplasty [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/hyaluronic-acid-injections-in-knee-osteoarthritis-patients-are-associated-with-delay-to-knee-arthroplasty/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyaluronic-acid-injections-in-knee-osteoarthritis-patients-are-associated-with-delay-to-knee-arthroplasty/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology